← Eichor
Study identifier: NCT05133882 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML

Condition: Acute Myeloid Leukemia, Adult  ·  Sponsor: Sunshine Lake Pharma Co., Ltd.

PhasePhase 1/Phase 2
Planned participants133
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a multi-center open clinical study aimed at evaluating the efficacy and safety of Clifutinib Besylate combined with chemotherapy in newly-treated adult subjects with AML

This description comes directly from the study's public registry record.

Talk to the study team

Jie Jin, Doctor  ·  0571-87236685  ·  jiej0503@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

the First Affiliated Hospital,College of Medicine,Zhejiang UniversityHanzhou, Zhejiang, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05133882